This post was originally published on this site A new approach using genetically modified T-cells — via CRISPR-Cas9 gene editing technology — safely and effectively targets cancer cells in patients with advanced multiple myeloma, preliminary data from a U.S.-based Phase 1 study show. Despite their preliminary nature, researchers believe these findings raise hope that this…
Conditions
Conditions
Opdivo-Avastin Combo Safe, Has Strong Activity in Relapsed Ovarian Cancer Patients, Phase 2 Trial Shows
This post was originally published on this site A combination of Opdivo (nivolumab) and Avastin (bevacizumab) is safe and has strong clinical activity in women with relapsed ovarian cancer, especially among those whose tumors were sensitive to platinum-based chemotherapy, a Phase 2 clinical trial shows. The study, “Assessment of Combined Nivolumab and Bevacizumab in Relapsed…
Phase 1 DRGT-45 Trial Doses First Patient With New Oral Formulation of Abiraterone Acetate
This post was originally published on this site A Phase 1 clinical trial testing DRGT-45 — a new oral formulation of abiraterone acetate — in men with prostate cancer has dosed its first participant, the treatment’s developer, Druggability Technologies (DRGT), announced. Abiraterone acetate is a form of hormone therapy already approved for men with advanced,…
Rare Disease Film Festival Highlights Patient and Researcher Unity
This post was originally published on this site Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly…
FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted fast track designation to Triumvira Immunulogics‘ investigational T-cell therapy TAC01-CD19 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The designation facilitates the development and review process of therapies that can treat severe conditions and…
Enrollment Completed for Phase 3 Trial Testing Provenge in Prostate Cancer Patients on Active Surveillance
This post was originally published on this site Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 trial assessing the safety and efficacy of its immunotherapy Provenge (sipuleucel-T) for men with early-stage prostate cancer on active surveillance, the company announced. The open-label ProVent trial (NCT03686683) included more than 450 participants…
Humana and Seniorlink Offering Tech-Enabled Coaching to Dementia Caregivers
This post was originally published on this site Expanding their existing relationship, Seniorlink and Humana are offering a program that provides additional care management and support to families caring for individuals with dementia, including Alzheimer’s disease. The dementia management program, which covers Humana Medicare Advantage members, capitalizes on Seniorlink’s experience and expertise in supporting caregivers. Specifically, it…
More Than $850M Raised for Inflammatory Breast Cancer Research
This post was originally published on this site Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation have joined to raise more than $850,000 for research targeting innovative diagnostic tools and therapy options, and to address questions and challenges in inflammatory breast cancer. Inflammatory breast cancer is a rare but…
Treatment With VBI-1901 Linked to Tumor Stabilization in Recurrent Gliobastoma Patients in Phase 1/2 Trial
This post was originally published on this site Immune responses triggered by the investigational cancer vaccine VBI-1901 correlate with the stabilization of tumor size in patients with recurrent glioblastoma (GBM), a common and aggressive brain cancer, according to new results from a Phase 1/2a clinical trial. The latest data from part A of the trial…
Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection
This post was originally published on this site The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory lymphomas positive for Epstein-Barr virus (EBV) infection. A therapy candidate is put on a fast track by the…
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy May Benefit Myeloma Patients, Phase 1 Trial Shows
This post was originally published on this site Adding the lymphoma therapy vorinostat to Revlimid (lenalidomide) maintenance therapy may deepen responses to stem cell transplants and prolong survival outcomes in multiple myeloma patients, long-term results of a Phase 1 clinical trial show. Results were published in the journal Biology of Blood and Marrow Transplantation in…
Ovarian Cancer Risk in Fertility Assistance Rises Mainly for Women with Endometriosis, Study Suggests
This post was originally published on this site Women who require assisted reproductive technology to become mothers are not more likely to develop ovarian cancer, except for those with endometriosis, a new study suggests. The study, “Assisted reproductive technology treatment and risk of ovarian cancer—a nationwide population-based cohort study,” was published in the journal Human…